Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 11/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169498 | 0.99 | MAPT (0.43) | MAPTKDM4ETSHRDPP4CTSS | |
| SCHEMBL6165071 | 0.78 | KDM4E (0.34) | MAPTKDM4ETSHRDPP4 | |
| SCHEMBL6774749 | 0.69 | MAPT (0.33) | MAPTTSHRDPP4DPP8DPP9 | |
| SCHEMBL6166675 | 0.69 | DPP4 (0.38) | DPP4CTSSDPP8DPP9 | |
| SCHEMBL22964983 | 0.64 | DPP4 (0.35) | TSHRDPP4DPP8DPP9PREP | |
| SCHEMBL4660548 | 0.63 | DPP4 (0.40) | DPP4DPP8DPP9PREPFAP | |
| SCHEMBL8342623 | 0.62 | DPP4 (0.32) | DPP4DPP8DPP9PREPFAP | |
| SCHEMBL28523847 | 0.61 | DPP4 (0.33) | DPP4DPP8DPP9PREPFAP | |
| SCHEMBL15756759 | 0.61 | CPN1 (0.31) | DPP4DPP8DPP9PREPFAP | |
| SCHEMBL3959337 | 0.61 | DPP4 (0.33) | DPP4DPP8DPP9PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465891-A4 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | GUILFORD PHARMACEUTICALS | 2005-03-31 | — | — | US | disclosed |
| EP-1465891-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057144-A2 | CHANGE INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057666-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP3, DPP7 | MAPT 1162/4885KDM4E 796/4885TSHR 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.